Search Results - ib3xxx

28 Results Sort By:
Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response
This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated...
Published: 7/25/2024   |   Inventor(s): Larry Anderson, Deborah Moore, Ralph Tripp
Keywords(s): bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Geriatrics
Development of Immune System Tolerance for the Treatment of Autoimmune Disease
The present invention provides a therapeutic method for the treatment of autoimmune or autoinflammatory diseases by first breaking down the dysregulated immune system and then reprogramming the immune system to restore tolerance to the patient's self-antigens by induction of antigen specific regulatory T cells. The inventors have shown that only with...
Published: 7/25/2024   |   Inventor(s): Wanjun Chen
Keywords(s): Alloantigen-specific, Apototic, CELL-MEDIATED, Cells, IB3XXX, IBXXXX, INDUCTION, IXXXXX, Patent Category - Biotechnology, Prevention, Regulatory, REJECTION, T, TRANSPLANT
Category(s): TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, Application > Therapeutics
Signatures of Genetic Control in Digestive and Liver Disorders
Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care...
Published: 7/25/2024   |   Inventor(s): Ralph Peace, Nicolaas Fourie, Sarah Abey, Wendy Henderson
Keywords(s): Acid, Altered, CAXXXX, CXXXXX, Digestive, DISORDERS, Expressions, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Identification, IXXXXX, Listed LPM Vepa as of 4/15/2015, liver, MESSENGER, MICRO, miRNA, PHENOTYPE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Ribonucleic, RNA, Species, THERAPY
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders
This technology provides novel antibodies and methods for diagnostics and treatment of disorders arising from dysregulation of the immune system using antibodies directed against glucocorticoid-induced tumor necrosis factor receptor family-related receptor ligand (GITRL). Also available are hybridomas producing anti-mouse GITRL monoclonal antibodies...
Published: 7/25/2024   |   Inventor(s): Ethan Shevach
Keywords(s): antibodies, AUTOIMMUNE DISEASE, CD25, CD4, GITR, GITRL, IB3XXX, IBXXXX, IDXXXX, immune response, immune suppressor, IXXXXX, Multiple sclerosis, Patent Category - Biotechnology, RHEUMATOID ARTHRITIS, T cell, Treg
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, Application > Therapeutics
Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis
The present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and...
Published: 7/25/2024   |   Inventor(s): Wei Zheng, Marc Ferrer-Alegre, Catherine Chen, Alexander Agoulnik, Noel Southall, Jingbo Xiao, Juan Marugan
Keywords(s): 1, IB1XXX, IB3XXX, IB5XXX, IB6XXX, IBXXXX, IXXXXX, MODULATORS, POTENT, RECEPTOR, Relaxin, RXFP1, SELECTIVE
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Cardiology, TherapeuticArea > Reproductive Health, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics
Potential Use of anti-IgE in the Treatment of Lupus Nephritis
Systemic lupus erythematosus (SLE) is a multi-organ inflammatory disease characterized by a significant morbidity and mortality related to both disease evolution as well as therapeutic side effects. At least half of SLE patients develop lupus nephritis. The inventors have used a Lyn -/- mouse model that develops an autoimmune disease exhibiting some...
Published: 7/30/2024   |   Inventor(s): Nicolas Charles, Juan Rivera
Keywords(s): antibodies, Anti-IgE, Are, AUTOREACTIVE, IB3XXX, IBXXXX, IGE, IXXXXX, Lupus, Nephritis, Nephritis:, PATHOLOGICAL, Potential, treatment
Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Immunology
AAV Mediated CTLA-4 Gene Transfer to Treat Sjogren's Syndrome
Sjögren’s syndrome is an autoimmune disease that affects over 2 million Americans, primarily over the age of 40. One of the major outcomes of Sjögren's syndrome is xerostomia (dry mouth) that is caused by immune system attack on moisture producing salivary glands. Researchers at the National Institute of Dental and Craniofacial Research have developed...
Published: 7/25/2024   |   Inventor(s): John (Jay) Chiorini, Hongen Yin
Keywords(s): Adeno-associated, Adeno-associated Virus, IB3XXX, IBXXXX, IXXXXX, Sjogren's, Sjogren's syndrome, Syndrome, T-LYMPHOCYTE, virus, Xerostomia
Category(s): Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Immunology
Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists
The Molecular Recognition Section of NIDDK announces the availability of a novel triazole-based probes, structures which act as antagonists at human P2Y14 receptors. Although the physiologic functions of this receptor remain undefined, recently it has been strongly implicated in immune and inflammatory responses. Prior work with a 4,7-disubstituted...
Published: 7/25/2024   |   Inventor(s): Evgeny Kiselev, Elisa Uliassi, Anna Junker, Kenneth Jacobson
Keywords(s): Alkyne, ANTAGONISTS, IB3XXX, IB4XXX, ID1XXX, P2Y14, Patent Category - Chemistry, Probe, RECEPTOR, small molecule, Structure-based, Triazole, VFXXXX, WIXXXX, WKXXXX, XHXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Endocrinology, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, TherapeuticArea > Pulmonology, Application > Research Materials
Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications
NIH Inventors have recently discovered a novel Leucine-rich repeat and calponin homology domain-containing protein 4 (Lrch4) in a proteomic screen of the plasma membrane of lipopolysaccharide (LPS)-exposed macrophages. Expression data by RT-PCR revealed that all Lrch family members (1-4) are expressed in macrophages, but only Lrch4 was recruited into...
Published: 7/25/2024   |   Inventor(s): Michael Fessler
Keywords(s): CB6XXX, CBXXXX, CXXXXX, DISEASES, GB1XXX, GBXXXX, GXXXXX, IB3XXX, IBXXXX, INFLAMMATORY, IXXXXX, Lrch4, Sepsis, TARGET, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases
Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment...
Published: 7/25/2024   |   Inventor(s): Matthew Boxer, Craig Thomas
Keywords(s): 1, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis 1; Amyotrophic lateral scleros, Amyotrophic lateral sclerosis 6, Caspase, IB3XXX, IBXXXX, Inflammatory bowel disease 1, inhibitor, IXXXXX, Lou Gehrig's disease, Patent Category - Chemistry
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Immunology
1 2 3 
© 2024. All Rights Reserved. Powered by Inteum